Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cempra Inc (CEMP)

Cempra Inc (CEMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,086
  • Shares Outstanding, K 52,510
  • Annual Sales, $ 18,020 K
  • Annual Income, $ -117,960 K
  • 60-Month Beta 0.99
  • Price/Sales 6.70
  • Price/Cash Flow N/A
  • Price/Book 0.85
Trade CEMP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.82
  • Most Recent Earnings -0.23 on 08/09/17
  • Next Earnings Date 11/09/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/17
See More
  • Average Estimate -0.16
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.21
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +74.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 +13.66%
on 10/27/17
3.40 -31.47%
on 10/04/17
-0.97 (-29.39%)
since 10/03/17
3-Month
2.05 +13.66%
on 10/27/17
4.40 -47.05%
on 08/09/17
-1.52 (-39.48%)
since 08/03/17
52-Week
2.05 +13.66%
on 10/27/17
9.40 -75.21%
on 11/07/16
-5.22 (-69.14%)
since 11/03/16

Most Recent Stories

More News
Gerd and Nerd Treatment Market Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2023

Kenneth Research has recently added a market research study on 2023 which provides a complete comprehensive analysis including the data by Segmentations, by Geography and as well as the competitive landscape...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
ESALF : 74.0500 (-2.57%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
VRX.TO : 30.80 (-3.33%)
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") today appointed Mr. Michael R. Dougherty to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc....

AVIR : 33.32 (-3.25%)
CEMP : 2.33 (+1.30%)
FMI : 136.95 (-0.04%)
JAZZ : 140.71 (-1.79%)
MRNS : 15.89 (+8.54%)
BSGM : 4.60 (-0.86%)
Gastro Esophageal Reflux Disease Drug and Devices Market 2019 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
MRK : 80.39 (+0.66%)
NVS : 90.83 (+1.19%)
PFE : 38.31 (+2.90%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Gastro Esophageal Reflux Disease Drug and Devices Market With Moderate CAGR in Forecast Period 2019 to 2026

The research includes a comprehensive analysis of market outlook, methodology and political-economic impacts. The report complies with estimated market size, share, product, revenue, and rate of advancement...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
MRK : 80.39 (+0.66%)
NVS : 90.83 (+1.19%)
PFE : 38.31 (+2.90%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Gastro Esophageal Reflux Disease Drug and Devices Market Latest In-Depth Report Segment by Manufacturers, Type, Applications and Dynamics

A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
MRK : 80.39 (+0.66%)
NVS : 90.83 (+1.19%)
PFE : 38.31 (+2.90%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Gerd and Nerd Treatment Market Overview and scope, Rising Demand, Share, Trends, Growth, Opportunities and Top Key 2023

Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid and Liquid), End User (Hospitals & Clinics, Research...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
ESALF : 74.0500 (-2.57%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
VRX.TO : 30.80 (-3.33%)
Americas GERD & NERD treatment market: key Vendors, Trends, Analysis, Segmentation, Forecast to 2018-2023

Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid and Liquid), End User (Hospitals & Clinics, Research...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
ESALF : 74.0500 (-2.57%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
VRX.TO : 30.80 (-3.33%)
Gastro Esophageal Reflux Disease Drug and Devices Market Is Expecting Revolutionary Growth in 2019 and Coming Years

The global Gastro Esophageal Reflux Disease Drug and Devices market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026....

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
MRK : 80.39 (+0.66%)
NVS : 90.83 (+1.19%)
PFE : 38.31 (+2.90%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Gerd & Nerd Treatment Market Industry Trends, Share, Size and Forecast Report By 2023

Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid and Liquid), End User (Hospitals & Clinics, Research...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
ESALF : 74.0500 (-2.57%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
VRX.TO : 30.80 (-3.33%)
The Americas GERD & NERD treatment market is anticipated to grow at the CAGR of 4.02% during the forecast period 2017-2023

Gerd & Nerd Treatment Market Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid and Liquid), End User (Hospitals & Clinics, Research...

AZN : 52.94 (+0.63%)
BSX : 33.15 (-1.34%)
CEMP : 2.33 (+1.30%)
ESALF : 74.0500 (-2.57%)
STIM : 8.61 (+1.89%)
GSK : 36.79 (-0.76%)
IRWD : 11.52 (-2.62%)
MDGS : 2.92 (-0.68%)
MDT : 113.70 (-0.78%)
VRX.TO : 30.80 (-3.33%)

Business Summary

Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance....

See More

Key Turning Points

2nd Resistance Point 2.44
1st Resistance Point 2.39
Last Price 2.33
1st Support Level 2.24
2nd Support Level 2.14

See More

52-Week High 9.40
Fibonacci 61.8% 6.59
Fibonacci 50% 5.72
Fibonacci 38.2% 4.86
Last Price 2.33
52-Week Low 2.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar